Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse transcriptase inhibitor.

DOI Web Site PubMed 26 References

Bibliographic Information

Other Title
  • 核酸系逆転写酵素阻害薬ジダノシン（バイデックス）の薬理作用と臨床効果
  • 新薬紹介総説 核酸系逆転写酵素阻害薬ジダノシン(ヴァイデックス)の薬理作用と臨床効果
  • シンヤク ショウカイ ソウセツ カクサンケイ ギャクテンシャ コウソ ソガイヤク ジダノシン ヴァイデックス ノ ヤクリ サヨウ ト リンショウ コウカ

Search this article

Description

An active metabolite, ddATP, of didanosine that is an analogue of purine-nucleoside (a component of nucleic acid) was known to inhibit the activity of DNA polymerase for E. coli. In 1985, Dr. Michiya et al. of NCI reported that didanosine and ddA inhibited replication of the human immunodeficiency virus (HIV). This discovery led to the clinical application of both the compounds. Didanosine, after being uptaken into a cell, becomes an active metabolite, ddATP, to inhibit a reverse transcriptase of HIV. Compared with zidovudine, didanosine has weak cytotoxicity both in vitro and in vivo. Didanosine, which is recommended as a first-line therapy drug in the Japanese Guideline on an anti-HIV Infection Therapy, was approved as twice-daily Videx Tablet and Dry Syrup formulations for launch in June 1992. In March 2001, a once-daily Videx EC Capsule formulation was approved and launched, having expected adherence improvements in HIV/AIDS patients.<br>

Journal

References(26)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top